Clinical Research Studies
Search our active and enrolling clinical research studies and see if you may qualify to participate.
While many people are familiar with heart disease and heart attacks, there’s another serious heart condition that impacts more than 5 million Americans, half of whom are age 65 and older. It’s called valvular heart disease (VHD), and it occurs when the heart valves do not work properly to keep blood flowing through the heart. Left untreated, heart valve disease can cause heart attacks, irregular heart rhythms, congestive heart failure and other heart conditions, significantly impacting a person’s quality of life and potentially leading to an untimely death. To help older adults in New Ulm, Minn., and the surrounding area determine if they might already have heart valve disease and not be aware of it, MHIF, in partnership with The Heart of New Ulm (HONU) and New Ulm Medical Center (NUMC), part of Allina Health, are conducting free heart valve disease screenings for eligible adults age 65 and older. The screenings, funded by the Abbott Northwestern Hospital Foundation, are part of an MHIF research project that is the first prospective population VHD screening study done in the United States.
Quitting smoking following acute coronary syndrome (ACS) can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS). Objective: For this R01 the investigators will evaluate the efficacy of using a single, integrated treatment that targets both depressed mood and smoking (BAT-CS).
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with iron deficiency and with a reduced ejection fraction.
This study will enroll patients who previously were not able to tolerate being on a statin medication due to muscle-related side effects. Research has shown that many people who have muscle symptoms on statin therapy do not experience the same side effects if they try it again later. This study is part of a larger effort to: See how common it is for patients to still be intolerant of statin medication after trying it a second time; and For those patients who do tolerate being on a statin after trying it a second time, see how common it is for them to still be taking the statin 3 months after completing the main part of the study.
Patients who agree to participate will be given a 5 month randomly allocated supply of statin and placebo and track their symptoms weekly.